October 27, 2016 09:53 AM EDTUpdated 10:18 AM

GSK dumps a late-stage HIV drug; MIT offers support for tech start-ups; Ra Pharma closes flat after $92M IPO

Shehla Shakoor

Managing Director

GlaxoSmithKline didn’t just kill losmapimod on Wednesday. The pharma giant was also forced to dump a late-stage HIV drug acquired from Bristol-Myers late last …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

GSK dumps a late-stage HIV drug; MIT offers support for tech start-ups; Ra Pharma closes flat after $92M IPO

Shehla Shakoor

Managing Director

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Are programs with compounded GLP-1s safe for your population?

GSK dumps a late-stage HIV drug; MIT of­fers sup­port for tech start-ups; Ra Phar­ma clos­es flat af­ter $92M IPO

Shehla Shakoor

Managing Director

Sign up to read this article for free.

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

GSK dumps a late-stage HIV drug; MIT offers support for tech start-ups; Ra Pharma closes flat after $92M IPO

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Are programs with compounded GLP-1s safe for your population?